Facebook Pixel Code Image Skip to main content
HSCB Logo

All Website dropdown

Recommend Technology Appraisals

Service notifications for recommended Technology Appraisals (TAs)

Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.

Health and Social Care Board service notifications are also available to download below.

NICE RefTitle and Link to NICE websiteDate issued by HSCBHSCB Service Notification
TA616TA 616 – Cladribine for treating relapsing-remitting multiple sclerosis7th August 2020
TA616 (0.3 MiB)
TA612Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2 positive early stage breast cancer after adjuvant trastuzumab27th January 2020
TA612 (43 KiB)
TA611Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer27th January 2020
TA611 (29 KiB)
TA607Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease3rd March 2020
TA607 (60 KiB)
TA600Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer23rd December 2019
TA600 (44 KiB)
TA598Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy23rd December 2019
TA598 (0.1 MiB)
TA596Risankizumab for treating moderate to severe plaque psoriasis. 2nd December 2019
TA596 (0.1 MiB)
TA595Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer6th December 2019
TA595 (29 KiB)
TA593Ribociclib with fulvestrant or treating hormone receptor-positive, HER2-negative, advanced breast cancer11th December 2019
TA593 (44 KiB)
TA592Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma17th October 2019
TA592 (29 KiB)
TA591Letermovir for preventing cytomegalovirus disease after a stem cell transplant17th October 2019
TA591 (29 KiB)
TA590Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis17th October 2019
TA590 (29 KiB)
TA589Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity17th October 2019
TA589 (55 KiB)
TA58819th May 2020
TA588 (42 KiB)
TA588Nusinersen for treating spinal muscular atrophy18th March 2020
TA588 (42 KiB)
TA586Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib17th October 2019
TA586 (42 KiB)
TA585Ocrelizumab for treating primary progressive multiple sclerosis4th October 2019
TA585 (30 KiB)
TA584Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer2nd October 2019
TA584 (43 KiB)
TA583Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes18th October 2019
TA583 (43 KiB)
TA581Nivolumab with ipilimumab for untreated advanced renal cell carcinoma2nd September 2019
TA581 (29 KiB)
TA579Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

 
14th August 2019
TA579 (43 KiB)
TA578Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation14th August 2019
TA578 (0.1 MiB)
TA577Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma2nd September 2019
TA577 (42 KiB)
TA575Tildrakizumab for treating moderate to severe plaque psoriasis.

 
27th August 2019
TA575 (44 KiB)
TA574Certolizumab pegol for treating moderate to server plague psoriasis.27th August 2019
TA574 (43 KiB)
TA573Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma14th August 2019
TA573 (29 KiB)
TA572Ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults14th August 2019
TA572 (43 KiB)
TA572Ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults14th August 2019
TA572 (43 KiB)
TA571Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib5th July 2019
TA571 (29 KiB)
TA567Enzalutamide for hormone-relapsed non-metastatic prostate cancer5th July 2019
TA567 (29 KiB)
TA563Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

 
5th July 2019
TA563 (32 KiB)
TA562Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

 
5th July 2019
TA562 (29 KiB)
TA561Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia.

 
25th July 2019
TA561 (33 KiB)
TA559Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies.

 
18th June 2019
TA559 (42 KiB)
TA558Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease.

 
18th June 2019
TA558 (89 KiB)
TA557Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer.

 
18th June 2019
TA557 (44 KiB)
TA555Regorafenib for previously treated advanced hepatocellular carcinoma19th April 2019
TA555 (0.1 MiB)
TA554Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years7th May 2019
TA554 (29 KiB)
TA553Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence.19th April 2019
TA553 (29 KiB)
TA552Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia7th March 2019
TA552 (91 KiB)
TA551Lenvatinib for untreated advanced hepatocellular carcinoma24th May 2019
TA551 (87 KiB)
TA547Tofacitinib for moderately to severely active ulcerative colitis1st April 2019
TA547 (28 KiB)
TA545Gemtuzumab ozogamicin for untreated acute myeloid leukaemia7th March 2019
TA545 (93 KiB)
TA544Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma14th February 2019
TA544 (16 KiB)
TA543Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs24th December 2018
TA543 (30 KiB)
TA542Cabozantinib for untreated advanced renal cell carcinoma31st January 2019
TA542 (41 KiB)
TA541Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia31st January 2019
TA541 (29 KiB)
TA540Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma9th April 2019
TA540 (44 KiB)
TA539Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.4th January 2019
TA539 (16 KiB)
TA539Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.28th January 2019
TA539 (16 KiB)
TA538Dinutuximab beta for treating neuroblastoma7th December 2018
TA538 (28 KiB)
TA537Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs24th December 2018
TA537 (30 KiB)
TA536Alectinib for untreated ALK-positive advanced non-small-cell lung cancer7th December 2018
TA536 (15 KiB)
TA535Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine7th December 2018
TA535 (29 KiB)
TA534Dupilumab for treating moderate to severe atopic dermatitis22nd January 2019
TA534 (33 KiB)
TA533Ocrelizumab for treating relapsing–remitting multiple sclerosis24th December 2018
TA533 (88 KiB)
TA531Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (review of TA447)20th November 2018
TA531 (29 KiB)
TA529Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer8th April 2019
TA529 (30 KiB)
TA528Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer28th March 2019
TA528 (44 KiB)
TA527Beta interferons and glatiramer acetate for treating multiple sclerosis (review of TA32)4th January 2019
TA527 (0.1 MiB)
TA526Arsenic trioxide for treating acute promyelocytic leukaemia3rd October 2018
TA526 (29 KiB)
TA525Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy22nd October 2018
TA525 (87 KiB)
TA524Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma3rd October 2018
TA524 (41 KiB)
TA523Midostaurin for untreated acute myeloid leukaemia11th September 2018
TA523 (15 KiB)
TA522Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable9th April 2019
TA522 (44 KiB)
TA521Guselkumab for treating moderate to severe plaque psoriasis3rd October 2018
TA521 (29 KiB)
TA519Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy2nd April 2019
TA519 (43 KiB)
TA518Tocilizumab for treating giant cell arteritis11th September 2018
TA518 (28 KiB)
TA517Avelumab for treating metastatic Merkel cell carcinoma9th April 2019
TA517 (44 KiB)
TA513Obinutuzumab for untreated advanced follicular lymphoma3rd August 2018
TA513 (28 KiB)
TA512Tivozanib for treating advanced renal cell carcinoma3rd August 2018
TA512 (16 KiB)
TA511Brodalumab fortreating moderate to severe plaque psoriasis.20th August 2018
TA511 (42 KiB)
TA510Daratumumab monotherapy for treating relapsed and refractory multiple myeloma28th March 2019
TA510 (43 KiB)
TA509Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer26th July 2018
TA509 (15 KiB)
TA508Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee28th September 2018
TA508 (31 KiB)
TA507Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C26th July 2018
TA507 (77 KiB)
TA505Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma27th March 2019
TA505 (43 KiB)
TA504 (Review of TA282)Pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282)20th August 2018
TA504 (Review of TA282) (29 KiB)
TA501Ibrutinib for treating relapsed or refractory mantle cell lymphoma.21st June 2018
TA501 (28 KiB)
TA500Ceritinib for untreated ALK-positive non-small-cell lung cancer.4th June 2018
TA500 (18 KiB)
TA499Glecaprevir–pibrentasvir for treating chronic hepatitis C.4th June 2018
TA499 (78 KiB)
TA498Lenvatinib with everolimus for previously treated advanced renal cell carcinoma7th June 2018
TA498 (33 KiB)
TA497Golimumab for treating non-radiographic axial spondyloarthritis22nd May 2018
TA497 (34 KiB)
TA496Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer22nd May 2018
TA496 (33 KiB)
TA495Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer22nd May 2018
TA495 (21 KiB)
TA493Cladribine tablets for treating relapsing–remitting multiple sclerosis4th April 2018
TA493 (0.1 MiB)
TA492Atezolozumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable19th August 2019
TA492 (43 KiB)
TA491Ibrutinib for treating Waldenstrom's macroglobulinaemia27th February 2019
TA491 (89 KiB)
TA490Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy.13th February 2019
TA490 (29 KiB)
TA488Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours14th March 2018
TA488 (0.1 MiB)
TA487Venetoclax for treating chronic lymphocytic leukaemia13th February 2019
TA487 (43 KiB)
TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer 11th February 2019
TA484 (43 KiB)
TA483
Nivolumab for previously treated squamous non-small-cell lung cancer
11th February 2019
TA483 (30 KiB)
TA482Immunosuppressive therapy for kidney transplant in children and young people (review of TA99)23rd March 2018
TA482 (36 KiB)
TA481Immunosuppressive therapy for kidney transplantation in adults (review of TA85)23rd March 2018
TA481 (62 KiB)
TA480Tofacitinib for moderate to severe rheumatoid arthritis19th February 2018
TA480 (46 KiB)
TA479Reslizumab for treating severe eosinophilic asthma19th February 2018
TA479 (0.1 MiB)
TA478Brentuximab vedotin for treating relapsed or efractory systemic anaplastic large cell lymphoma9th February 2018
TA478 (46 KiB)
TA477Autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (review of TA89)9th February 2018
TA477 (45 KiB)
TA476Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (review of TA360)12th January 2018
TA476 (59 KiB)
TA475Dimethyl fumarate for treating moderate to severe plaque psoriasis)18th January 2018
TA475 (46 KiB)
TA474Sorafenib for treating advanced hepatocellular carcinoma (review of TA189)9th January 2018
TA474 (91 KiB)
TA473Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (review of TA172)9th January 2018
TA473 (46 KiB)
TA472Obinutuzumab with bendamustine for treating follicular lymphoma refractory to
rituximab
8th February 2019
TA472 (17 KiB)
TA471Eluxadoline for treating irritable bowel syndrome with diarrhoea5th January 2018
TA471 (62 KiB)
TA467Holoclar for treating limbal stem cell deficiency after eye burns 9th January 2018
TA467 (0.1 MiB)
TA466Baricitinib for moderate to severe rheumatoid arthritis21st March 2018
TA466 (46 KiB)
TA464Bisphosphonates for treating osteoporosis (part review of TA160 and TA161)21st March 2018
TA464 (45 KiB)
TA463Cabozantinib for previously treated advanced renal cell carcinoma21st March 2018
TA463 (35 KiB)
TA462Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma6th December 2017
TA462 (32 KiB)
TA461Roflumilast for treating severe chronic obstructive pulmonary disease in adults with
chronic bronchitis
21st March 2018
TA461 (46 KiB)
TA460Adalimumab and dexamethasone for treating non-infectious uveitis6th December 2017
TA460 (61 KiB)
TA459Collagenase clostridium histolyticum for treating Dupuytren’s6th December 2017
TA459 (46 KiB)
TA458Trastuzumab emtansine for treating HER2 positive advanced breast cancer after trastuzumab and a taxane (review of TA371)28th November 2017
TA458 (33 KiB)
TA457Carfilzomib for previously treated multiple myeloma6th December 2017
TA457 (44 KiB)
TA456Ustekinumab for moderately to severely active Crohn’s disease after previous treatment21st November 2017
TA456 (0.1 MiB)
TA455Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people21st November 2017
TA455 (46 KiB)
TA451Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia8th November 2017
TA451 (58 KiB)
TA450Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia8th November 2017
TA450 (0.1 MiB)
TA449Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease8th November 2017
TA449 (47 KiB)
TA448Etelcalcetide for treating secondary hyperparathyroidism6th December 2017
TA448 (45 KiB)
TA446Brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma31st October 2017
TA446 (58 KiB)
TA443Obeticholic acid for treating primary biliary cholangitis14th September 2017
TA443 (69 KiB)
TA442Ixekizumab for treating moderate to severe plaque psoriasis31st August 2017
TA442 (58 KiB)
TA441Daclizumab for treating relapsing-remitting multiple sclerosihttphttp31st August 2017
TA441 (0.1 MiB)
TA439Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (review of TA176 & part review of TA439)24th August 2017
TA439 (61 KiB)
TA433Apremilast  for treating active psoriatic arthritis after inadequate response to DMARDs.19th July 2017
TA433 (45 KiB)
TA432Everolimus for advanced renal cell carcinoma after previous treatment (review of TA219)19th June 2017
TA432 (32 KiB)
TA431Mepolizumab for treating severe refractory eosinophilic asthma.26th May 2017
TA431 (60 KiB)
TA430Sofosbuvir-velpatasvir for treating chronic hepatitis C.23rd May 2017
TA430 (0.2 MiB)
TA429Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation.23rd May 2017
TA429 (44 KiB)
TA428Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy.18th May 2017
TA428 (58 KiB)
TA427Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338).18th May 2017
TA427 (32 KiB)
TA426Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (review of TA251 & part review of TA70)4th May 2017
TA426 (35 KiB)
TA425Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (review of TA241 & part review TA70).4th May 2017
TA425 (48 KiB)
TA424Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer4th May 2017
TA424 (33 KiB)
TA423Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens14th April 2017
TA423 (60 KiB)
TA422Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (review of TA296).14th April 2017
TA422 (92 KiB)
TA421Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (review of TA295)​14th April 2017
TA421 (32 KiB)
TA420Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction31st March 2017
TA420 (0.2 MiB)
TA419Ticagrelor Apremilast for treating moderate to severe plaque psoriasis (review of TA368)5th April 2017
TA419 (72 KiB)
TA418Dapagliflozin in triple therapy for treating type 2 diabetes (part review of TA288)31st March 2017
TA418 (44 KiB)
TA417Nivolumab for treated or metastatic renal cell carcinoma30th March 2017
TA417 (58 KiB)
TA415Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor2nd March 2017
TA415 (58 KiB)
TA413Elbasvir-grazoprevir for treating chronic hepatitis C2nd March 2017
TA413 (0.2 MiB)
TA412Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases26th January 2017
TA412 (47 KiB)
TA410Talimogene laherparepvec for treating metastatic melanoma26th January 2017
TA410 (50 KiB)
TA409Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion2nd February 2017
TA409 (50 KiB)
TA408Pegaspargase for treating acute lymphoblastic leukaemia2nd February 2017
TA408 (0.1 MiB)
TA407Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors2nd February 2017
TA407 (49 KiB)
TA406Crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer26th January 2017
TA406 (33 KiB)
TA404Degarelix for treating advanced hormone-dependent prostate cancer5th January 2017
TA404 (35 KiB)
TA402Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (Review of TA309)5th January 2017
TA402 (49 KiB)
TA401Bosutinib for previously treated chronic myeloid leukaemia (Review of TA299)5th January 2017
TA401 (49 KiB)
TA400Nivolumab in combination with ipilimumab for treating advanced melanoma2nd December 2016
TA400 (0.1 MiB)
TA397Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus7th November 2016
TA397 (0.1 MiB)
TA396Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) melanoma31st October 2016
TA396 (36 KiB)
TA395Ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer28th October 2016
TA395 (0.1 MiB)
TA394Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia28th October 2016
TA394 (52 KiB)
TA393Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia28th October 2016
TA393 (52 KiB)
TA392Adalimumab for treating moderate to severe hidradenitis suppurativa28th October 2016
TA392 (50 KiB)
TA391Cabazitaxel for hormone relapsed metastatic prostate cancer treated with docetaxel (review of TA255)7th October 2016
TA391 (69 KiB)
TA390Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes3rd November 2016
TA390 (46 KiB)
TA389Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer.14th September 2016
TA389 (0.1 MiB)
TA388Sacubitril valsartan for treating heart failure with systolic dysfunction31st August 2016
TA388 (0.3 MiB)
TA387Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated31st August 2016
TA387 (0.1 MiB)
TA386Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis31st August 2016
TA386 (52 KiB)
TA385Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (review of TA1325th July 2016
TA385 (0.1 MiB)
TA384Nivolumab for treating advanced (unresectable or metastatic) melanoma2nd August 2016
TA384 (51 KiB)
TA383TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (including a review of TA143 and TA233).16th June 2016
TA383 (0.1 MiB)
TA381Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.16th June 2016
TA381 (61 KiB)
TA380Panobinostat for treating multiple myeloma after at least 2 previous treatments.16th June 2016
TA380 (0.1 MiB)
TA379Nintedanib for treating idiopathic pulmonary fibrosis16th June 2016
TA379 (65 KiB)
TA377Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.16th June 2016
TA377 (64 KiB)
TA376Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases16th June 2016
TA376 (0.1 MiB)
TA375Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed16th June 2016
TA375 (0.1 MiB)
TA374Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy6th May 2016
TA374 (49 KiB)
TA373Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)16th June 2016
TA373 (0.1 MiB)
TA370Ciclosporin for treating dry eye disease which has not improved after treatment with artificial tears.25th April 2016
TA370 (93 KiB)
TA369Bortezomib for previously untreated mantle cell lymphoma.16th June 2016
TA369 (92 KiB)
TA367Vortioxetine for treating major depressive disorder25th April 2016
TA367 (91 KiB)
TA366Pembrolizumab for advanced melanoma not previously treated with ipilimumab25th April 2016
TA366 (35 KiB)
TA365Ombitasvir, paritaprevir, ritonavir with or without dasabuvir for treating chronic hepatitis C25th April 2016
TA365 (0.1 MiB)
TA364Daclatasvir for treating chronic hepatitis C25th April 2016
TA364 (0.1 MiB)
TA363Ledipasvir-sofosbuvir for treating chronic hepatitis C25th April 2016
TA363 (0.1 MiB)
TA360Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer24th November 2015
TA360 (0.1 MiB)
TA359Idelalisib for previously treated chronic lymphocytic leukaemia25th April 2016
TA359 (50 KiB)
TA358Tolvaptan for treating autosomal dominant polycystic kidney disease25th April 2016
TA358 (0.1 MiB)
TA357Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab25th April 2016
TA357 (64 KiB)
TA355Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation25th April 2016
TA355 (0.1 MiB)
TA354Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism23rd December 2015
TA354 (0.1 MiB)
TA352Vedolizumab for the treatment of adult patients with moderately to severely active Chron’s disease23rd December 2015
TA352 (0.1 MiB)
TA350Secukinumab for treating moderate to severe plaque psoriasis13th October 2015
TA350 (50 KiB)
TA349Dexamethasone intravitreal implant for treating diabetic macular oedema20th November 2015
TA349 (0.1 MiB)
TA347Nintedanib for previously treated local advanced metastic or locally recurrent non-small cell lung cancer20th November 2015
TA347 (35 KiB)
TA346Aflibercept for treating diabetic macular oedema13th October 2015
TA346 (0.1 MiB)
TA345Naloxegol for treating opioid induced constipation20th November 2015
TA345 (37 KiB)
TA343 TA344Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic joint with untreated chronic lymphocytic leukaemia (joint with TA344)13th October 2015
TA343 TA344 (0.1 MiB)
TA342Vedolizumab for treating moderately to severely active ulcerative colitis13th October 2015
TA342 (0.1 MiB)
TA341Apixaban for the treatment and secondary prevention and/or pulmonary embolism13th October 2015
TA341 (0.1 MiB)
TA340Ustekinumab for treating active psoriatric arthritis (Rapid Review of TA13)13th October 2015
TA340 (0.1 MiB)
TA339Omalizumab for treating previously treated chronicspontaneous urticaria13th October 2015
TA339 (49 KiB)
TA337Rifaximin for the maintenance treatment of hepatic encephalopathy13th October 2015
TA337 (34 KiB)
TA336Empagliflozin in combination therapy for treating type 2 diabetes13th October 2015
TA336 (0.1 MiB)
TA335Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome13th October 2015
TA335 (0.1 MiB)
TA333Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systematic treatment13th October 2015
TA333 (39 KiB)
TA331Simeprevir in combination with peginterferon alfa and ribavirin for treating genotpe 1 or 4 chronic hepatitis C13th October 2015
TA331 (36 KiB)
TA330Sofosbuvir for treating chronic hepatitis C13th October 2015
TA330 (0.1 MiB)
TA329Infliximabk, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)13th October 2015
TA329 (0.1 MiB)
TA327Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism13th October 2015
TA327 (0.1 MiB)
TA326Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196)13th October 2015
TA326 (37 KiB)
TA325Nalmefene for reducing alcohol consumption in people with alcohol dependence13th October 2015
TA325 (0.3 MiB)
TA324Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block23rd March 2015
TA324 (0.1 MiB)
TA323Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)13th October 2015
TA323 (39 KiB)
TA322Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality28th January 2015
TA322 (49 KiB)
TA321Dabrafenib for treating unresectable or metastatic BRAF V6oo mutation-positive melanoma25th February 2015
TA321 (39 KiB)
TA320Dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.28th January 2015
TA320 (0.2 MiB)
TA319Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma.29th January 2015
TA319 (37 KiB)
TA318Lubiprostone for treating chronic idiopathic constipation29th January 2015
TA318 (34 KiB)
TA317Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)29th January 2015
TA317 (33 KiB)
TA315Canagliflozin in combination therapy for treating Type 2 Diabetes22nd October 2014
TA315 (35 KiB)
TA314Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120)25th November 2014
TA314 (45 KiB)
TA312Alemtuzumab for treating adults with relapsing– remitting multiple sclerosis16th October 2014
TA312 (36 KiB)
TA311Bortezomib for induction therapy in multiplemyeloma before high-dose chemotherapy and autologous stem cell transplantation.16th October 2014
TA311 (39 KiB)
TA310Afatinib for treating epidermal growth factor receptormutation positive locally advanced or metastatic non- small cell lung cancer29th August 2014
TA310 (33 KiB)
TA308Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis28th January 2015
TA308 (31 KiB)
TA306Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma20th May 2014
TA306 (45 KiB)
TA305Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion7th July 2014
TA305 (44 KiB)
TA304Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip7th July 2014
TA304 (30 KiB)
TA303Teriflunomide for treating relapsing–remitting multiple sclerosis20th May 2014
TA303 (34 KiB)
TA301Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy2nd April 2014
TA301 (33 KiB)
TA300Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people2nd April 2014
TA300 (34 KiB)
TA294Aflibercept solution for injection for the first line treatment of wet age-related macular degeneration14th October 2013
TA294 (31 KiB)
TA293Eltrombopag for the treatment of chronic idiopathic(immune) thrombocytopenic purpura (review of technology appraisal 205)26th November 2013
TA293 (34 KiB)
TA292Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder24th January 2014
TA292 (39 KiB)
TA290Mirabegron for treating symptoms of overactivebladder19th November 2013
TA290 (84 KiB)
TA288Dapagliflozin in combination therapy for treatingtype 2 diabetes26th November 2013
TA288 (31 KiB)
TA287Rivaroxaban for treating pulmonary embolism andpreventing recurrent venous thromboembolism19th November 2013
TA287 (0.3 MiB)
TA283Ranibizumab for treating visual impairment causedby macular oedema secondary to retinal vein occlusion14th October 2013
TA283 (48 KiB)
TA280Abatacept for the treatment of rheumatoid arthritisonly after the failure of conventional disease- modifying anti-rheumatic drugs (rapid review of TA234)11th September 2013
TA280 (33 KiB)
TA279Percutaneous vertebroplasty and percutaneousballoon kypoplasty for treating osteoporotic vertebral compression fractures25th September 2013
TA279 (58 KiB)
TA278Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201)11th September 2013
TA278 (54 KiB)
TA276Colistimethate sodium and tobramycin dry powdersfor inhalation for treating pseudomonas lung infection in cystic fibrosis21st August 2013
TA276 (52 KiB)
TA275Apixaban for the prevention of stroke and systemicembolism in people with non-valvular atrial fibrillation24th July 2013
TA275 (52 KiB)
TA274Ranibizumab for treating diabetic macular oedema(rapid review of technology appraisal guidance 237)24th July 2013
TA274 (43 KiB)
TA269Vemurafenib for treating locally advanced ormetastatic BRAF V600 mutation malignant melanoma24th July 2013
TA269 (39 KiB)
TA268Ipilimumab for previously treated advanced(resectable or metastatic) melanoma24th July 2013
TA268 (51 KiB)
TA267Ivabradine for treating chronic heart failure24th July 2013
TA267 (42 KiB)
TA266Mannitol dry powder for inhalation for treating cysticfibrosis24th July 2013
TA266 (36 KiB)
TA265Denosumab for the prevention of skeletal-relatedevents in adults with bone metastases from solid tumours24th July 2013
TA265 (47 KiB)
TA264Alteplase for treating acute ischaemic stroke (reviewof technology appraisal guidance 122).24th July 2013
TA264 (25 KiB)
TA261Rivaroxaban for the treatment of deep veinthrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism24th July 2013
TA261 (32 KiB)
TA260Botulinum toxin type A for the prevention ofheadaches in adults with chronic migraine24th July 2013
TA260 (0.2 MiB)
TA259Abiraterone for castration resistant metastatic prostatecancer previously treated with a docetaxel-containing regimen24th July 2013
TA259 (0.1 MiB)
TA258Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer24th July 2013
TA258 (0.2 MiB)
TA256Rivaroxaban for the prevention of stroke andsystemic embolism in people with atrial fibrillation24th July 2013
TA256 (53 KiB)
TA254Fingolomob for the treatment of relapsing-remitting multiple sclerosis20th May 2013
TA254 (0.1 MiB)
TA252 TA253Boceprevir for the treatment of genotype 1 chronic hepatitis CTelaprevir for the treatment of genotype 1 chronic hepatitis C20th May 2013
TA252 TA253 (37 KiB)
TA251Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70)20th May 2013
TA251 (0.1 MiB)
TA249Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation24th July 2013
TA249 (54 KiB)
TA248Diabetes (type 2) –  Exenatide (prolonged-release)20th May 2013
TA248 (37 KiB)
TA247Rheumatoid arthritis –  tocilizumab20th May 2013
TA247 (35 KiB)
TA246Venom anaphylaxis – immunotherapy pharmalgen20th May 2013
TA246 (0.2 MiB)
TA245Venous thromboembolism- apixaban (hip and knee surgery)20th May 2013
TA245 (0.1 MiB)
TA244Chronic obstructive pulmonary disease- roflumilast20th May 2013
TA244 (24 KiB)
TA243Follicular lymphoma- rituximab (review of TA 110)20th May 2013
TA243 (0.2 MiB)
TA241Dasatinib, high dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid luekaemia (CML)20th May 2013
TA241 (33 KiB)
TA238Tocilizumab for the treatment of systemic juvenile idiopathic arthritis20th May 2013
TA238 (0.2 MiB)
TA236Ticagrelor for acute coronary syndromes 20th May 2013
TA236 (0.2 MiB)
TA235Mifamurtide for the treatment of osteosarcoma3rd October 2014
TA235 (39 KiB)
NICE Ref Title Date Issued by HSCB
TA234 Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA233 Golimumab for the treatment of ankylosing spondylitis 20/02/2012
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 05/01/2012
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction 05/01/2012
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion 05/01/2012
TA228 Bortezomib and thalidomide for the firstline treatment of multiple myeloma 05/01/2012
TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer 05/01/2012
TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma 05/01/2012
TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs 20/02/2012
TA223 Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 05/01/2012
TA222 Trabectedin for the treatment of relapsed ovarian cancer 05/01/2012
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura 05/01/2012
TA220 Golimumab for the treatment of psoriatic arthritis 20/02/2012
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 05/01/2012
TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma 05/01/2012
TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer 05/01/2012
TA203 Liraglutide for the treatment of type 2 diabetes mellitus 20/02/2012
TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis 20/02/2012
TA198 Tocilizumab for the treatment of rheumatoid arthritis 05/01/2012
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation 20/02/2012
TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia 05/01/2012
TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer 05/01/2012
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children 05/01/2012
TA187 Infliximab (review) and adalimumab for the treatment of Crohn’s disease 05/01/2012
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis 20/02/2012
TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma 05/01/2012
TA166 Cochlear implants for children and adults with severe to profound deafness 05/01/2012
TA98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents 14/09/2016
TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA23 Temozolomide for the treatment of recurrent malignant gliomaC 02/08/2016
TA20 Riluzole for the treatment of Motor Neurone Disease 01/08/2016